Evidence map›Paper›PMID 41121270›Full record

ArticleOrphanet journal of rare diseases2025

Danon disease in male patients: a prospective natural history study to augment understanding of the phenotype.

Tarek Khedro, Jennifer Attias, Emily Eshraghian, Melina Tsotras, Emily Margolin, Shaden Yassin, Elizabeth Silver, Quan Bui, Shyamanga Borooah, Chamindra G Laverty and 3 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tarek KhedroDepartment of Internal Medicine, Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA.
Jennifer AttiasDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Emily EshraghianDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Melina TsotrasDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Emily MargolinDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Shaden YassinDepartment of Ophthalmology, University of California San Diego, San Diego, CA, USA.
Elizabeth SilverDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Quan BuiDepartment of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Shyamanga BorooahDepartment of Ophthalmology, University of California San Diego, San Diego, CA, USA.
Chamindra G LavertyDepartment of Neurology, School of Medicine, University of California San Diego, San Diego, CA, USA.
Matthew R G TaylorAdult Medical Genetics Program, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Eric D Adler *Department of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Kimberly N Hong *Department of Cardiology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA. knhong@health.ucsd.edu.ORCID 0000-0003-3293-138X

Funding

Rocket Rocket
6 · The paper itself

Abstract

backgroundDanon disease (DD) is a rare X-linked cardioskeletal myopathy caused by pathogenic mutations in lysosomal-associated membrane protein-2 (LAMP2). It is a multisystemic disease that affects the heart, skeletal, neurologic and ophthalmic systems. With an early age of onset especially in males and no treatment for the cardiomyopathy outside of heart transplant, natural history studies have been paramount to providing clinical data for the development and advancement of disease-focused therapies. Herein we present a comprehensive, prospective study detailing both cardiac and extracardiac features of DD.

methodsThe cohort was comprised of 8 male pediatric and 1 male young adult patient, enrolled at the University of California, San Diego. Diagnosis of DD was confirmed with a pathogenic or likely pathogenic LAMP2 variants. The patients underwent serial quality of life, neuropsychological, cognitive, ophthalmological, cardiac, pulmonary, and neuromuscular assessments every 6 months for 3 years.

resultsThe mean age of the cohort at study enrollment was 11.6 ± 4.5 years. The mean age of the cohort at diagnosis was 6.5 ± 5.2 years. Quality of life: assessed through the Pediatric Cardiac Quality of Life Inventory (PCQLI) and Pediatric Quality of Life Inventory (PQLQ) reveals perceptions of poor quality of life by both patients and parents. Cognitive: Differential Ability Scales-II (DAS-II) and Vineland Adaptive Behavior Scales-3 (VABS-3) showed marked intellectual disability at baseline. Cardiac: over time, ejection fraction decreased, myocardial walls thickened, and left ventricular mass increased. Pulmonary: FVC increased over time; cardiopulmonary exercise testing (CPET) revealed decreased exercise capacity as measured by peak oxygen uptake (peak VO2 max) and 6-minute walk test (6MWT). Neuromuscular: most patients in the cohort achieved maximum scores on North Star Ambulatory Assessment (NSAA), with minimal changes over 6-month follow-up; they were faster than a study of normal children during the 10-meter walk test (10MWT); they were slower than a study of normal children during time to rise and the 4-stair climb test.

conclusionNatural history studies provide an important opportunity to study rare diseases, especially when longitudinal data is available to characterize clinical changes and disease course. In the case of DD, young, male patients were found to have general deficits across quality-of-life indices and cognitive, cardiac, neuromuscular, ophthalmologic, and pulmonary functions. Stabilization or improvements in these domains may be appropriate outcomes for clinical trials to consider.

Indexed as

Glycogen Storage Disease Type IIbAdolescentChildChild, PreschoolHumansLysosomal-Associated Membrane Protein 2MalePhenotypeProspective StudiesQuality of LifeYoung AdultLAMP2 protein, humanLysosomal-Associated Membrane Protein 2Danon diseaseDifferential ability Scales-II (DAS-II)Lysosomal-associated membrane protein 2 (LAMP2)Nonischemic genetic cardiomyopathyNorth star ambulatory assessment (NSAA)Pediatric cardiac quality of life inventory (PCQLI)Pediatric quality of life inventory (PQLQ)Vineland adaptive behavior scales-3 (VABS-3)

Identifiers

PMID41121270
PMCPMC12542076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.